Margaret G. Kelly

Clinical and biochemical effects of cyclophosphamide in patients with malignant carcinoid

Abstract Six patients with malignant carcinoid disease were given eight courses of therapy with cyclophosphamide. Measurable antitumor effect (decrease in liver size) was variable but decreases in liver size of 40 per cent or greater were noted in four of the eight trials. Symptoms of the carcinoid syndrome exacerbated shortly after the initial administration of the drug. Elevation of urinary 5-HIAA levels and the appearance of other metabolites in the urine occurred consistently with the initial intravenous dose of drug.